Devyser Diagnostics AB (publ) (STO:DVYSR)
Sweden · Delayed Price · Currency is SEK 64.30
-0.50 (-0.77%)
Nov 4, 2026, 5:29 PM CET
Devyser Diagnostics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 253.6 | 250.5 | 216.9 | 169.3 | 126.6 | 93.48 | |
Revenue Growth | 4.45% | 15.49% | 28.12% | 33.73% | 35.43% | 42.31% |
Cost of Revenue | 50.6 | 48.6 | 44.2 | 24.5 | 23.2 | 21.57 |
Gross Profit | 203 | 201.9 | 172.7 | 144.8 | 103.4 | 71.91 |
Selling, General & Admin | 157.9 | 173.3 | 193.1 | 163.5 | 132.1 | 75.65 |
Research & Development | 17.7 | 18 | 43.1 | 37.8 | 26.3 | 18.07 |
Other Operating Expenses | -2.3 | -1 | -1 | -0.3 | -0.2 | -0.12 |
Operating Expenses | 173.3 | 190.3 | 235.2 | 201 | 158.2 | 93.6 |
Operating Income | 29.7 | 11.6 | -62.5 | -56.2 | -54.8 | -21.69 |
Interest Expense | - | -3 | -3.5 | -0.8 | -0.5 | -0.94 |
Interest & Investment Income | 6.6 | 0.9 | 4.2 | 5 | 0.3 | 0.01 |
Earnings From Equity Investments | - | - | - | - | - | 0.37 |
Currency Exchange Gain (Loss) | -12.1 | -12.2 | 4.7 | -2.3 | 1.2 | 0.06 |
Other Non Operating Income (Expenses) | 6.6 | 0.1 | -0.1 | - | - | 0.22 |
EBT Excluding Unusual Items | 30.8 | -2.6 | -57.2 | -54.3 | -53.8 | -21.97 |
Gain (Loss) on Sale of Investments | - | - | - | - | 1.6 | - |
Gain (Loss) on Sale of Assets | - | - | -0.4 | -0.4 | 0.1 | 0.07 |
Asset Writedown | - | - | - | 0.3 | -0.7 | -0 |
Pretax Income | 30.8 | -2.6 | -57.6 | -54.4 | -52.8 | -21.91 |
Income Tax Expense | 5.3 | 5.8 | 3.9 | -0.8 | -6.8 | -1.18 |
Net Income | 25.5 | -8.4 | -61.5 | -53.6 | -46 | -20.73 |
Net Income to Common | 25.5 | -8.4 | -61.5 | -53.6 | -46 | -20.73 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 17 | 17 | 16 | 16 | 16 | 11 |
Shares Outstanding (Diluted) | 17 | 17 | 16 | 16 | 16 | 11 |
Shares Change | 1.59% | 1.34% | 1.63% | 1.63% | 41.78% | 28.98% |
EPS (Basic) | 1.52 | -0.51 | -3.75 | -3.31 | -2.89 | -1.85 |
EPS (Diluted) | 1.50 | -0.51 | -3.75 | -3.31 | -2.89 | -1.85 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 56.7 | 6.7 | -76.5 | -81.2 | -48.4 | -18.68 |
Free Cash Flow Per Share | 3.37 | 0.40 | -4.65 | -5.02 | -3.04 | -1.66 |
Gross Margin | 80.05% | 80.60% | 79.62% | 85.53% | 81.67% | 76.93% |
Operating Margin | 11.71% | 4.63% | -28.82% | -33.20% | -43.29% | -23.20% |
Profit Margin | 10.05% | -3.35% | -28.35% | -31.66% | -36.34% | -22.17% |
Free Cash Flow Margin | 22.36% | 2.67% | -35.27% | -47.96% | -38.23% | -19.98% |
EBITDA | 44.8 | 20.1 | -56 | -52.5 | -52.6 | -20.99 |
EBITDA Margin | 17.67% | 8.02% | -25.82% | -31.01% | -41.55% | -22.46% |
D&A For EBITDA | 15.1 | 8.5 | 6.5 | 3.7 | 2.2 | 0.69 |
EBIT | 29.7 | 11.6 | -62.5 | -56.2 | -54.8 | -21.69 |
EBIT Margin | 11.71% | 4.63% | -28.82% | -33.20% | -43.29% | -23.20% |
Effective Tax Rate | 17.21% | - | - | - | - | - |